Oxalate Induced Correction of the Plasma Antithromboplastin Deficiency in the Aging Arteriosclerotic Subject^[*]

Summary

Intravenous heparin will correct the enhanced thromboplastin generation of oxalated plasma obtained from the human arteriosclerotic patient. It will not,

however, correct the deficiency of antithromboplastin activity in non-oxalated plasma obtained from the pathological subject. This deficiency of antithromboplastin disappears if oxalate ion is introduced into the heparinized plasma.

^* This study has been supported in part by the U.S. Public Health Service Grant No. H-3697, American and Minnesota Heart Associations, Life Insurance Medical Research Fund, and the University of Minnesota Graduate School.

• References

• 1 Koller F. Über die klinische Bedeutung der Blutgerinnungsstörungen. Schweiz, med. Wschr. 1945; 290.
• 2 Koller F. Die Prophylaxe und Therapie der Thrombose mit Antikoagulantien. Helv. med. Acta. 16: 184 1949;
• 3 Gormsen J. Heparin resistance, thromboplastin generation and glass activation. Thrombos. Diathes. haemorrh. (Stuttg) 06: 144 1961;
• 4 Schram A. C, Pilgeram L. O. Correlation of activity changes in blood coagulation factors with human arteriosclerosis. Circulation 20: 991 1959;
• 5 Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Path. 06: 23 1953;
• 6 Spaet T. H, Garner E. S. Inactivation of thromboplastin in human blood. J. clin. Invest 34: 1807 1955;
• 7 Cruz W. O. L, Meis L, Dietrich C. P. “In vitro” neutralization with oxalate ion of the anticoagulant effect of heparin. Thrombos. Diathes. haemorrh. (Stuttg) 05: 314 1960;
• 8 Seegers W. H, Warner E. D, Brinkhous K. M, Smith H. P. Heparin and the antithrombic activity of plasma. Science 96: 300 1942;
• 9 Monkhouse F. C. Relationship between antithrombin and thrombin levels in plasma and serum. Amer. J. Physiol. 197: 984 1959;